Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (-paclitaxel) in metastatic breast cancer: which benefit for which patients?
The therapeutic goals in metastatic breast cancer (MBC) remain palliative in nature, aimed at controlling symptoms, improving or maintaining quality of life and prolonging survival. The advent of new drugs and new formulations of standard agents has led to better outcomes in patients with advanced o...
Main Authors: | Raffaella Palumbo, Federico Sottotetti, Antonio Bernardo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016639873 |
Similar Items
-
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
by: Palumbo R, et al.
Published: (2015-04-01) -
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
by: E V Artamonova
Published: (2017-01-01) -
Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
by: Md Sazzad Hassan, et al.
Published: (2018-04-01) -
Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis
by: Xin Li, et al.
Published: (2019-10-01) -
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians
by: Raffaella Palumbo, et al.
Published: (2013-11-01)